3,4-Methylenedioxy-N-propylamphetamine

3,4-Methylenedioxy-N-propylamphetamine (MDPR) is a lesser-known psychoactive drug and a substituted amphetamine. MDPR was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown.^[1] MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH.^[1]

MDPR

Clinical data
Routes of administration	Oral[1]
Drug class	Psychoactive drug[1]
ATC code	None
Pharmacokinetic data
Duration of action	Unknown[1]
Identifiers
IUPAC name N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]propan-1-amine
CAS Number	74698-36-5 Y
PubChem CID	559375
ChemSpider	486273
UNII	B4W69BKX3L
ChEMBL	ChEMBL197038
CompTox Dashboard (EPA)	DTXSID50339877
ECHA InfoCard	100.217.125
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(NCCC)Cc1ccc2OCOc2c1
InChI InChI=1S/C13H19NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h4-5,8,10,14H,3,6-7,9H2,1-2H3 Key:LBXMQBTXOLBCCA-UHFFFAOYSA-N
(verify)

Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD,^[1] and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7.^[1] The reason for this synergistic action of MDPR has not been elucidated.^[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPR other than what is written in PiHKAL.^[1]

See also

• Substituted methylenedioxyphenethylamine
• Phenylpropylaminopentane
• Benzofuranylpropylaminopentane
• MDAL